X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Avenzo will develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally, excluding Greater China.
Lead Product(s): AVZO-021,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: ARTS-021
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avenzo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the agreement, AstraZeneca will develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $540.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement January 02, 2024
Details:
The financing will support the upcoming Phase I/II clinical trials in both China and the U.S. and the identification of clinical candidates for additional programs including ARTS-011, an allosteric inhibitor targeting the TYK2 pseudokinase domain, for autoimmune diseases.
Lead Product(s): ARTS-011
Therapeutic Area: Dermatology Product Name: ARTS-011
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: INCE Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 09, 2023
Details:
The proceeds will be used to support Allorion's preclinical projects, IND-enabling studies and IND applications of two drug candidates in China and the United States.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: IDG Capital
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
